Long-term results of a phase 2 trial in 98 patients with medically inoperable peripheral stage I–II NSCLC: SBRT 30 Gy in 1 fraction vs 60 Gy in 3 fractions showed no new adverse events and no differences in local or distant failure, PFS or OS. Median survival was 40.3 months.
RCTn = 98
Singh et al. Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial